United States Patent 7,253,185 Scope and Claims Analysis: Pharmaceutical Composition Covering Kernel-Linked R1/R2/R3 Substituted Ring Systems

Executive summary: US 7,253,185 claims a class of pharmaceutical compositions containing a kernel-linked substituted compound (with defined substituent-variable groups R1, R2, R3) formulated with a pharmaceutically acceptable carrier/excipient. The independent claim 1 establishes broad structural-genus coverage driven by (i) R1 hydrophobic/aromatic or aliphatic substituents with strict size and unsaturation constraints, (ii) R2 as a C6 to C8 alkyl handle, and (iii) R3 as a saturated N-heterocycle (pyrrolidine, azetidine, or piperidine) attached via the nitrogen to the kernel. Dependent claims 2 and 4 narrow R1 to specific para- and fused-ring substituted phenyl options. The enforceable scope is primarily composition-by-structure (not method-of-use), and the patent’s practical litigation leverage typically turns on whether an accused product uses a covered compound within the R1/R2/R3 constraints and whether its formulation uses a pharmaceutically acceptable carrier (which is usually satisfied for finished dosage forms).

What does US 7,253,185 claim at a high level: kernel-linked compound genus in pharmaceutical compositions?

Core claim type: “A pharmaceutical composition comprising a compound represented by the following structural formula … and a pharmaceutically acceptable carrier or excipient, wherein …”

Key takeaways from the claim architecture:

Composition claim, not process claim. The preamble and body require a composition containing:
- a specific structural family (the compound defined by kernel + R1/R2/R3), plus
- a pharmaceutically acceptable carrier/excipient.
Genus coverage at the compound level. The independent claim uses variable substituents (R1/R2/R3) to cover a family of analogs rather than a single molecule.
Constraint-driven boundaries. The genus is broad, but each substituent variable has defined chemical constraints. Those constraints are the “litigation fault lines” because an accused product can avoid infringement by moving outside any required constraint.

How does the “kernel” concept limit the claim?

The claims as provided reference “the following structural formula” and “wherein: R1… R2… R3… attached to the kernel.” In practice, this means:

The kernel is the conserved core scaffold (not reproduced in your excerpt).
R1, R2, R3 define the allowed substitutions on that kernel.

For infringement, claim construction will treat the “kernel” as the fixed structural nucleus, while the R groups define allowable modifications.

What is the scope of Claim 1 in US 7,253,185: how do R1, R2, and R3 define the covered chemical space?

Claim 1 elements (as given):

A pharmaceutical composition comprising:
- a compound represented by the structural formula (or stereoisomer, salt, or mixture),
- pharmaceutically acceptable carrier/excipient,
- with substituent definitions:
  - R1 is:
    - phenyl or substituted phenyl, or
    - branched aliphatic group, or
    - C7–C15 alkyl chain or C7–C15 alkenyl chain with a double bond next to the kernel (regiochemical constraint implied by “next to the kernel”).
  - R2 is an alkyl group C6, C7, or C8.
  - R3 is a pyrrolidine, azetidine, or piperidine with the nitrogen attached to the kernel (N-linkage requirement).

R1 coverage: aromatic, branched aliphatic, and long-chain alkyl/alkenyl

Claim 1’s R1 definition is the main breadth driver.

R1 categories:

Aromatic R1
- Phenyl
- substituted phenyl (generic substitution permitted at this level of the claim, but dependent claims narrow to certain substituents)
Aliphatic R1
- branched aliphatic group (no explicit carbon count in claim excerpt, so the claim relies on “branched aliphatic” ordinary meaning plus kernel adjacency)
- linear long-chain alkyl C7–C15
- long-chain alkenyl C7–C15 with the double bond adjacent to the kernel (this is a key constraint that can be used for design-around if unsaturation position changes)

Practical boundary risk for an accused product:
Any R1 that falls outside these categories (for example, short-chain alkyl under C7, unbranched shorter alkyl, or alkenyl with double bond not “next to the kernel”) can support noninfringement.

R2 coverage: narrow carbon-count handle (C6–C8)

R2 is limited to alkyl C6 to C8. That is a relatively tight numerical constraint.

Design-around lever: changing R2 to C5 or C9 can remove coverage without needing to alter the rest of the scaffold.
If an accused product uses a different alkyl length at that position, it is outside Claim 1’s R2 requirement.

R3 coverage: N-heterocycles with N attached to kernel

R3 options are:

pyrrolidine
azetidine
piperidine
and critically:
nitrogen atom attached to the kernel (connectivity requirement)

Design-around lever:
Switching to a heterocycle where the attachment is not through the nitrogen (for example, an O-linked morpholine analog in place of a N-linked piperidine) is a likely route out of literal coverage.

Stereoisomers, salts, and mixtures

Claim 1 also explicitly covers:

stereoisomers,
pharmaceutically acceptable salts,
mixtures.

That matters for infringement because even if a product uses a different stereochemical form, it stays within claim scope if within the defined structural genus and not excluded by dependent limitations.

What does Claim 2 narrow in US 7,253,185: which para-substituted phenyl groups qualify as R1?

Claim 2 depends from Claim 1 and narrows R1. It states R1 is a phenyl group substituted with functional group selected from:

p-methoxy
hydroxyl
methylenedioxy
ethylenedioxy
trimethylenedioxy
cyclohexyl

Impact on scope:

Claim 2 is narrower than Claim 1 and provides additional fallback position(s) for enforcement.
It also signals that the patent drafter considered specific aromatic substitution patterns as commercially relevant or technically emphasized.

Litigation use:

In validity/enforcement disputes, dependent claims often help maintain an enforceable core if some embodiments of the broader independent claim face prior art or indefiniteness pressure.
If an accused product uses exactly one of these R1 substitutions, it may directly fall within Claim 2 as well (depending on whether other R groups match).

What is the scope of Claim 3 in US 7,253,185: which R3 substituents and R1 variants are additionally covered?

Claim 3 depends from a similar base composition structure and states:

R1 is:
- substituted or unsubstituted phenyl,
- branched aliphatic group,
- or C7–C15 alkyl or C7–C15 alkenyl with a double bond next to the kernel.
R2 is alkyl C6–C8.
R3 is pyrrolidine only, and nitrogen attached to kernel.

Key difference vs Claim 1:

Claim 1 allows pyrrolidine, azetidine, or piperidine as R3.
Claim 3 limits R3 to pyrrolidine only.

So Claim 3 is an R3-subset refinement.

Design-around lever relative to Claim 1:
If an accused product uses azetidine or piperidine as the R3 linked N-heterocycle, it can still fall under Claim 1, but it would not match Claim 3.

What does Claim 4 narrow in US 7,253,185: which R1 phenyl substitutions qualify when R3 is pyrrolidine?

Claim 4 is dependent on Claim 3 and narrows R1 exactly to the same functional group list provided in Claim 2:

p-methoxy
hydroxyl
methylenedioxy
ethylenedioxy
trimethylenedioxy
cyclohexyl

Enforcement posture:

Claim 4 creates a specific aromatic substitution corridor for products that also have pyrrolidine as R3.

How do salts, stereoisomers, and mixtures affect infringement risk under US 7,253,185?

Because Claim 1 expressly includes “a stereoisomer, a pharmaceutically acceptable salt or a mixture thereof,” infringement risk is typically broadened for three reasons:

Stereochemistry swaps are not a guaranteed design-around. A different stereoisomer can still be within the claim if the structural genus conditions remain met.
Salt selection is less protective. Pharmaceutically acceptable salt forms are included.
Combination products with mixture claims can still land in-scope if the mixture contains a compound falling within the claimed structure and the composition includes the claimed compound with an acceptable carrier.

What formulations are covered by US 7,253,185: does the claim cover dosage forms or only “carrier-excipient” compositions?

Based on the claim text provided, the patent is drafted at the level of:

“pharmaceutical composition comprising [compound genus] + pharmaceutically acceptable carrier or excipient.”

That language is usually interpreted broadly to cover essentially any finished dosage form where the active is in a pharmaceutical carrier, including:

tablets, capsules, pellets,
oral liquids, suspensions,
injectables (assuming pharmaceutically acceptable excipients),
topical forms if they use pharmaceutically acceptable carriers.

But the enforceable limit is structural: the product must still contain an in-scope compound defined by the kernel + R1/R2/R3 structure.

What generic entry risks exist under US 7,253,185: when can a generic or alternative salt avoid infringement?

Literal infringement screening checklist (composition claims)

For an accused generic/alternative to be safe, it typically must fail at least one of the essential claim requirements:

Does the active ingredient fall within the kernel-defined compound genus?
Is R1 inside the allowed set?
- aromatic phenyl/substituted phenyl, branched aliphatic, or C7–C15 alkyl/alkenyl with the defined unsaturation location
Is R2 exactly C6, C7, or C8 alkyl?
Is R3 one of pyrrolidine/azetidine/piperidine (Claim 1) or pyrrolidine only (Claim 3)?
Is the heterocycle attached through nitrogen to the kernel?
Is the product a “pharmaceutical composition” with a pharmaceutically acceptable carrier/excipient?
- Usually yes for FDA-approved products

Common design-around pathways

Change R2 carbon length (move off C6–C8).
Change R3 heterocycle (if it must remain N-linked) or change connectivity (non-N attachment).
For R1 alkenyl analogs, change double bond placement so it is not “next to the kernel.”
Replace phenyl substitution patterns with substituents not intended to meet the dependent claim lists (though that only matters if the independent claim is already met via the broader R1 language).

What patent landscape issues matter for enforcing US 7,253,185: is this a stand-alone composition claim or part of a family?

US 7,253,185 as framed by your claim excerpt is a high-level composition claim with:

a kernel-defined scaffold and variable substituents,
explicit inclusion of stereoisomers and salts,
dependent narrowing on R1 aromatic functional groups.

In practice, composition claims of this structure are frequently supported by:

related process claims (manufacturing),
related intermediate claims (synthetic intermediates),
related method-of-use claims (if the patent family extends to therapeutic activity),
additional formulation claims (if separate patents cover dosage forms or specific excipient systems).

However, since you have provided only the claims text for this specific patent (and not the full family dossier, prosecution history, or related patents), this analysis remains confined to scope of this patent’s claims rather than the breadth of the entire family.

Claim scope matrix: US 7,253,185 coverage boundaries by R-group and dependency

Claim	Required R3	Allowed R1 (high-level)	R2 constraint	R1 specific functional group limitation	Notes
Claim 1	Pyrrolidine or azetidine or piperidine (N attached)	Phenyl/substituted phenyl; branched aliphatic; C7–C15 alkyl; C7–C15 alkenyl with double bond next to kernel	Alkyl C6, C7, C8	None	Broadest in provided set
Claim 2	Same as Claim 1	Phenyl substituted with: p-methoxy, hydroxyl, methylenedioxy, ethylenedioxy, trimethylenedioxy, cyclohexyl	Alkyl C6, C7, C8	Yes	Narrow aromatic fallback
Claim 3	Pyrrolidine only (N attached)	Same high-level R1 options as Claim 1	Alkyl C6, C7, C8	None	Narrowed by R3 only
Claim 4	Pyrrolidine only (N attached)	Same R1 functional group list as Claim 2	Alkyl C6, C7, C8	Yes	Narrowest provided set

How strong is the enforceable patent estate for US 7,253,185 based on claim drafting structure?

Within this patent alone, strength indicators are:

Genus composition claim tied to multiple substituent variables, giving flexibility in asserted embodiments.
Explicit inclusion of stereoisomers and pharmaceutically acceptable salts, which reduces common product form “escape hatches.”
Connectivity requirement for R3 (N attached to kernel), which helps avoid overbreadth while preserving meaningful claim boundaries.
Numerical constraint for R2 (C6–C8), which is a litigation handle that can either limit or clarify scope.

Enforcement limitation within this patent:

If an accused product’s active ingredient does not match the kernel or any required R-group constraint, the composition claim generally fails.
The provided claims do not indicate method-of-use coverage, so enforcement against indirect infringement typically depends on product-specific composition facts rather than therapeutic usage.

What patent litigation and Paragraph IV challenges typically turn on for US composition-genus claims like 7,253,185?

For composition-by-structure patents, Paragraph IV challenges and litigation pivot on:

Claim construction: whether the R-group definitions are interpreted strictly (especially “double bond next to the kernel” and N-connectivity).
Infringement mapping: whether the accused active ingredient sits inside the allowed R1/R2/R3 boundaries.
Validity defenses: anticipation/obviousness against the claimed genus and dependent sub-genus (Claims 2 and 4).

This patent’s dependent claim narrowing on specific aromatic substituents often affects validity arguments because those sub-genus embodiments can be either closer to prior art or further away depending on the art.

Key Takeaways

US 7,253,185 is a composition claim covering a kernel-linked structural genus with defined substituents R1/R2/R3 plus pharmaceutically acceptable carrier/excipient.
Claim 1 is broadest, with R3 = pyrrolidine/azetidine/piperidine and R2 = C6–C8 alkyl; R1 supports aromatic phenyl, branched aliphatic, and long-chain alkyl/alkenyl (with a positional unsaturation constraint for alkenyl).
Claims 2 and 4 narrow R1 to a specific set of phenyl functional groups, providing a narrower fallback corridor.
Claim 3 narrows R3 to pyrrolidine only; Claim 4 combines pyrrolidine-only R3 with the same narrowed R1 functional group list.
Stereoisomers and pharmaceutically acceptable salts are included, reducing formulation/salt-based design-around options.

FAQs

1) Does US 7,253,185 cover only the exact compound or also its stereoisomers and salts?

It covers the compound “or a stereoisomer” and “a pharmaceutically acceptable salt or a mixture thereof,” provided the compound still fits the kernel + R1/R2/R3 structural constraints.

2) Can a product avoid infringement by using a different salt form of the same active?

Under the claim language provided, “pharmaceutically acceptable salt” is included, so changing salt form alone does not avoid infringement if the active structure remains within the claimed genus.

3) What is the most straightforward chemical design-around lever in the claim?

The R2 carbon count is limited to C6–C8 alkyl. Moving R2 outside C6–C8 can remove coverage without needing to alter R1/R3.

4) If an accused compound uses piperidine attached through nitrogen, is it within US 7,253,185?

If it also matches the kernel and the R1/R2 constraints, piperidine with nitrogen attached to the kernel falls within Claim 1’s R3 options.

5) How do Claims 2 and 4 change the scope compared with Claim 1 and Claim 3?

Claims 2 and 4 restrict R1 to a defined set of substituted phenyl functional groups; they are narrower fallback embodiments versus the broader R1 categories in Claims 1 and 3.

References (APA)

United States Patent and Trademark Office. (n.d.). US Patent 7,253,185.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	5929600	⤷ Start Trial
Australia	774960	⤷ Start Trial
Brazil	0012318	⤷ Start Trial
Canada	2378600	⤷ Start Trial
Canada	2454453	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,253,185

Summary for Patent: 7,253,185